Pelareorep Clinical Trials (2026): 10 Studies for Recurrent Plasma Cell Myeloma & Anal Cancer Metastatic
Hipa.ai Research · Source: ClinicalTrials.gov / AACT
Synced daily from ClinicalTrials.gov via AACT. Last sync: .
10 Pelareorep clinical trials are catalogued on Hipa.ai from the AACT mirror of ClinicalTrials.gov, spanning 9 indications (including Recurrent Plasma Cell Myeloma & Anal Cancer Metastatic) and 449 total planned enrollment. 1 Pelareorep clinical trial is actively recruiting at 5 U.S. sites across 4 states. Most recent activity: NCT07446322 (Apr 2030).
Where to Participate: All Pelareorep Trial Sites in the U.S. (5 sites across 4 states)
Every actively recruiting Pelareoreptrial site, sorted by state then city. Each row links to the trial detail page (eligibility, contacts, full study record). Sites no longer enrolling at the location level are excluded. ClinicalTrials.gov / AACT does not provide street-level addresses; the map link uses the facility's geocoded coordinates where available.
| State | Facility | City | Trial | Map |
|---|---|---|---|---|
| AL | Central Alabama Research | Homewood35209 | NCT07446322 | Map |
| GA | Emory Winship Cancer Institute | Atlanta30302 | NCT07446322 | Map |
| NJ | Summit Health Cancer Center | Florham Park07932 | NCT07446322 | Map |
| NJ | Rutgers Cancer Institute | New Brunswick08901 | NCT07446322 | Map |
| OH | Gabrail Cancer Center | Canton44718 | NCT07446322 | Map |
Pelareorep clinical trials at a glance: phase × recruitment status
| Phase | recruiting | active not recruiting | completed | terminated | Total |
|---|---|---|---|---|---|
| Early P1 | 1 | 1 | |||
| P1 | 3 | 3 | |||
| P1/P2 | 2 | 2 | |||
| P2 | 1 | 2 | 1 | 4 |
Recruiting Pelareorep clinical trials (1)
Studies currently enrolling participants. Click any NCT ID to view the trial detail page (eligibility, sites, contacts).
| NCT ID | Title | Phase | Indication | Enrollment | Started |
|---|---|---|---|---|---|
| NCT07446322 | FOLFIRI and Bevacizumab With or Without Pelareorep for Second-Line Treatment of Metastatic RAS-Mutated, Microsatellite-Stable Colorectal Cancer | P2 | Ras-mutated Metastatic Colorectal Cancer | 60 | Apr 2026 |
Pelareorep clinical trials by indication
Recurrent Plasma Cell Myeloma (2)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT05514990 | — | P1/P2 | active not recruiting | Bortezomib and Pembrolizumab With or Without Pelareorep for the Treatment of Relapsed or Refractory Multiple Myeloma, AMBUSH Trial |
| NCT03605719 | — | P1 | completed | Dexamethasone, Carfilzomib, & Nivolumab With Pelareorep for Relapsed/Refractory Multiple Myeloma |
Ras-mutated Metastatic Colorectal Cancer (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT07446322 | — | P2 | recruiting | FOLFIRI and Bevacizumab With or Without Pelareorep for Second-Line Treatment of Metastatic RAS-Mutated, Microsatellite-Stable Colorectal Cancer |
Anal Cancer Metastatic (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT07280377 | GOBLET | P1/P2 | active not recruiting | A Study in Advanced or Metastatic Gastrointestinal Cancers Exploring Treatment Combinations With Pelareorep and Atezolizumab |
Advanced or Metastatic Breast Cancer (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT05519059 | — | P1 | completed | Pelareorep and Paclitaxel Injection in Chinese Patients With Advanced or Metastatic Breast Cancer |
Anatomic Stage IV Breast Cancer AJCC v8 (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT04445844 | — | P2 | active not recruiting | INCMGA00012 and Pelareorep for the Treatment of Metastatic Triple Negative Breast Cancer, IRENE Study |
Breast Cancer Metastatic (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT04215146 | — | P2 | active not recruiting | A Study to Assess Overall Response Rate by Inducing an Inflammatory Phenotype in Metastatic BReast cAnCEr With the Oncolytic Reovirus PeLareorEp in CombinaTion With Anti-PD-L1 Avelumab and Paclitaxel - BRACELET-1 Study |
Breast Cancer (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT04102618 | AWARE-1 | Early P1 | terminated | A Window-of-opportunity Study of Pelareorep in Early Breast Cancer |
Anemia (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT02101944 | — | P1 | completed | Wild-Type Reovirus in Combination With Carfilzomib and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma |
Recurrent Fallopian Tube Carcinoma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT01199263 | — | P2 | completed | Paclitaxel With or Without Viral Therapy in Treating Patients With Recurrent or Persistent Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer |
Terminated and withdrawn Pelareorep trials (1)
Studies that ended before completion. Reasons are filed in each trial's ClinicalTrials.gov entry.
- NCT04102618terminatedA Window-of-opportunity Study of Pelareorep in Early Breast Cancer
All Pelareorep trials (10)
Sorted by most recent activity (completion → start → posted date). Each row links to the trial detail page on Hipa.ai.
| NCT ID | Acronym | Title | Phase | Status | Enrollment | Sponsor | Started |
|---|---|---|---|---|---|---|---|
| NCT07446322 | FOLFIRI and Bevacizumab With or Without Pelareorep for Second-Line Treatment of Metastatic RAS-Mutated, Microsatellite-Stable Colorectal Cancer | P2 | recruiting | 60 | Oncolytics Biotech | Apr 2026 | |
| NCT07280377 | GOBLET | A Study in Advanced or Metastatic Gastrointestinal Cancers Exploring Treatment Combinations With Pelareorep and Atezolizumab | P1/P2 | active not recruiting | 122 | Oncolytics Biotech | Oct 2021 |
| NCT05514990 | Bortezomib and Pembrolizumab With or Without Pelareorep for the Treatment of Relapsed or Refractory Multiple Myeloma, AMBUSH Trial | P1/P2 | active not recruiting | 10 | University of Southern California | Oct 2022 | |
| NCT04445844 | INCMGA00012 and Pelareorep for the Treatment of Metastatic Triple Negative Breast Cancer, IRENE Study | P2 | active not recruiting | 25 | Mridula George, MD | Jul 2020 | |
| NCT04215146 | A Study to Assess Overall Response Rate by Inducing an Inflammatory Phenotype in Metastatic BReast cAnCEr With the Oncolytic Reovirus PeLareorEp in CombinaTion With Anti-PD-L1 Avelumab and Paclitaxel - BRACELET-1 Study | P2 | active not recruiting | 48 | Oncolytics Biotech | Jun 2020 | |
| NCT02101944 | Wild-Type Reovirus in Combination With Carfilzomib and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma | P1 | completed | 12 | National Cancer Institute (NCI) | Dec 2014 | |
| NCT05519059 | Pelareorep and Paclitaxel Injection in Chinese Patients With Advanced or Metastatic Breast Cancer | P1 | completed | 15 | Adlai Nortye Biopharma Co., Ltd. | Oct 2021 | |
| NCT03605719 | Dexamethasone, Carfilzomib, & Nivolumab With Pelareorep for Relapsed/Refractory Multiple Myeloma | P1 | completed | 23 | Emory University | Oct 2018 | |
| NCT04102618 | AWARE-1 | A Window-of-opportunity Study of Pelareorep in Early Breast Cancer | Early P1 | terminated | 26 | Oncolytics Biotech | Mar 2019 |
| NCT01199263 | Paclitaxel With or Without Viral Therapy in Treating Patients With Recurrent or Persistent Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer | P2 | completed | 108 | National Cancer Institute (NCI) | Dec 2010 |
Pelareorep clinical trials: frequently asked questions
- How many Pelareorep clinical trials are there?
- 10 Pelareorep clinical trials are catalogued on Hipa.ai, sourced from the AACT mirror of ClinicalTrials.gov. 1 is actively recruiting participants. 4 are marked completed.
- Are Pelareorep clinical trials recruiting in 2026?
- Yes — 1 Pelareorep trial is actively recruiting in 2026, with 5 U.S. sites across 4 states. See the recruiting trials and the per-state site list further down this page.
- What conditions is Pelareorep being studied for?
- Pelareorep is being studied for Recurrent Plasma Cell Myeloma, Anal Cancer Metastatic, Anatomic Stage IV Breast Cancer AJCC v8, Anemia, Breast Cancer and 18 more. The trials are grouped by indication on this page.
- What phase is Pelareorep in?
- Pelareorep clinical trials span 4 Phase 2, 3 Phase 1. The phase × status matrix at the top of this page breaks down counts by phase and recruitment status.
- Who sponsors Pelareorep clinical trials?
- The lead sponsor across the most Pelareorep trials is Oncolytics Biotech, with 5 additional lead sponsors listed in the data. Each trial row links to the full study detail page including sponsor information.
Sources and methodology
Trial inventory derived from the AACT mirror of ClinicalTrials.gov. Trials are filtered to those naming Pelareorepas an intervention. Phase, status, enrollment, sponsor, and dates are taken from the source `studies` table; primary indication is the first listed condition. Acronyms are extracted from each trial's brief title where present. PubMed links are populated for trials whose published primary outcomes have been indexed in our evidence cache.
Last refreshed .
Related pages on Hipa.ai: